公开(公告)号：US20170182090A1

公开(公告)日：2017-06-29

申请号：US15456497

申请日：2017-03-11

Applicant: Braintree Laboratories, Inc.

Inventor： Mark vB Cleveland ,  John S. Fordtran ,  Edmund V. Dennett

IPC: A61K33/04 ,  A61K9/00

CPC classification number: A61K33/04 ,  A61K9/0095 ,  A61K2300/00

Abstract: The present invention is generally directed to an oral pharmaceutical composition comprising a sulfate salt, for example, sodium sulfate and/or potassium sulfate, wherein the composition is substantially free of magnesium sulfate. The present invention is further directed to use of such oral pharmaceutical compositions to induce laxation or to treat or prevent constipation, e.g., opioid-induced constipation.

公开(公告)号：US20240415875A1

公开(公告)日：2024-12-19

申请号：US18743526

申请日：2024-06-14

Applicant: Braintree Laboratories, Inc.

Inventor： Edmund V. Dennett ,  Mark Cleveland ,  Russell W. Pelham ,  Matthew Walker

IPC: A61K31/765 ,  A61K9/08 ,  A61K33/04 ,  A61K47/02 ,  A61K47/26 ,  A61P1/10

Abstract: Disclosed herein are methods of administering compositions comprising a mixture of salts that induce purgation of the colon and are useful to cleanse the colon. Furthermore, the disclosed methods prevent degradation of PEG and allow for cleansing of the colon without the use of adjunct laxatives, including stimulant laxatives such as bisacodyl. The disclosed methods are superior to the prior art in that they allow for higher tolerability, improved safety, lower volumes, and improved patient compliance.

公开(公告)号：US20240415876A1

公开(公告)日：2024-12-19

申请号：US18792849

申请日：2024-08-02

Applicant: Braintree Laboratories, Inc.

Inventor： Edmund V. Dennett ,  Mark Cleveland ,  Russell W. Pelham ,  Matthew Walker

IPC: A61K31/765 ,  A61K9/08 ,  A61K33/04 ,  A61K47/02 ,  A61K47/26 ,  A61P1/10

Abstract: Disclosed herein are methods of administering compositions comprising a mixture of salts that induce purgation of the colon and are useful to cleanse the colon. Furthermore, the disclosed methods prevent degradation of PEG and allow for cleansing of the colon without the use of adjunct laxatives, including stimulant laxatives such as bisacodyl. The disclosed methods are superior to the prior art in that they allow for higher tolerability, improved safety, lower volumes, and improved patient compliance.